PhilHealth’s new circular puts first-line TB drugs on GAMOT. Run that pharmacy track now, or keep TB medicine only inside TB-DOTS?

legal_basis: [
  {
    "source_id": "phic-circ-2026-0018-pdf",
    "claim": "First-line DS-TB drugs into GAMOT as a supplemental track; TB-DOTS under Circular 2014-0014 remains primary; case rates 4,875.00 / 2,437.50 intensive and 2,925.00 / 1,462.50 continuation as printed."
  },
  {
    "source_id": "ra-11223-juris-sec1-2",
    "claim": "RA 11223 Sections 1-2 as printed: access to curative services without financial hardship is the policy the circular operationalizes."
  },
  {
    "source_id": "news-hmoph-phic-0018",
    "claim": "November 1 start; covered anti-TB medicines not deducted from the 20,000-peso annual GAMOT limit; one-month supply per transaction; two-day dispense; automatic 50-percent deduction."
  },
  {
    "source_id": "jurisdiction-philhealth-doh-ntp",
    "claim": "DOH National TB Program Manual of Procedures, 6th edition, still governs the regimen."
  },
  {
    "source_id": "q-gamot-or-tbdots-only",
    "claim": "The question is the supplemental GAMOT dispense track versus keeping first-line medicines inside TB-DOTS only."
  }
]

burden: {
  "who_pays": "PhilHealth, through existing TB-DOTS case rates and the GAMOT benefit; patients only where the two-day dispense window is missed, as HMOph printed.",
  "who_administers": "PhilHealth with accredited GAMOT facilities and prescribing physicians; the DOH National TB Program governs the regimen.",
  "who_is_harmed_if_wrong": "DS-TB patients if two channels fragment adherence; the National Health Insurance Fund if the 50-percent deduction is applied to the wrong base and one regimen is paid twice."
}

prediction: {
  "claim": "The supplemental track starts on the printed November 1 date, and the first measurable failures, if any, appear at the two-day dispense window rather than as drug stockouts.",
  "horizon": "first quarter of implementation, through 31 January 2027",
  "metric": "PhilHealth or news print of claims volume under the GAMOT TB track, and reports of out-of-pocket incidents at the dispense window."
}

cost_estimate: {
  "narrative": "No new peso is published. The cost sits inside existing TB-DOTS case rates and the 20,000-peso annual GAMOT limit, with the carve-out keeping TB medicines from consuming that limit. A national TB-drug peso total is not published."
}

confidence: 0.68
prior_art: []
prior_art_verification: pending_verification

legal_basis: [
  {
    "source_id": "phic-circ-2026-0018-pdf",
    "claim": "The PDF establishes GAMOT dispensing of first-line DS-TB drugs as supplemental, keeps TB-DOTS primary, bans split sourcing within a phase, and prints the phase claim figures."
  },
  {
    "source_id": "news-hmoph-phic-0018",
    "claim": "HMOph reported the November 1 start, the two-day dispense window, the ₱20,000 carve-out, and the automatic 50% deduction."
  },
  {
    "source_id": "ra-11223-juris-sec1-2",
    "claim": "RA 11223 §2 sets UHC policy of access to curative services without financial hardship."
  }
]

burden: {
  "who_pays": "PhilHealth's benefit fund pays GAMOT facilities for drugs and pays TB-DOTS facilities a reduced claim when drugs are sourced through GAMOT.",
  "who_administers": "PhilHealth administers claims; accredited primary-care clinics prescribe; accredited GAMOT facilities dispense; DOH's National TB Program protocols govern the regimen.",
  "who_is_harmed_if_wrong": "DS-TB patients if the dispense window or stock gaps interrupt treatment; TB-DOTS facilities if reduced claims weaken their case management."
}

prediction: {
  "claim": "Within six months of the HMOph-reported November 1 start, PhilHealth will publish or be asked to publish data on GAMOT-dispensed TB drug claims, and will issue a clarification on the dispense window or the claim deduction.",
  "horizon": "By 30 June 2027",
  "metric": "Count of GAMOT anti-TB claims versus full TB-DOTS claims per phase; number of patients reported paying out of pocket after a missed dispense window; any amending or clarifying PhilHealth issuance."
}

cost_estimate: {
  "narrative": "No national TB-drug peso figure has been published. The PDF prints per-phase claim amounts for TB-DOTS facilities; the GAMOT drug reimbursement amounts and total program cost have not been published. HMOph reported that these medicines will not count against the ₱20,000 annual GAMOT limit, so the cost falls on the fund rather than the member's benefit cap."
}

confidence: 0.65
prior_art: []
prior_art_verification: pending_verification